Results 161 to 170 of about 74,225 (263)

Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism

Breast Cancer: Targets and Therapy
Mingya Zhu,1 Yongqin Liu,1 Zhu Wen,1 Hao Tan,1 Siman Li,1 Xinkang Yu,1 Hongping Luo,1 Delin Li,1 Jinyan Wang,1 Fangyan Qin2 1Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2The Second People’s ...
Zhu M, Liu Y, Wen Z, Tan H, Li S, Yu X, Luo H, Li D, Wang J, Qin F   +9 more
doaj  

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source

Context‐Dependent Radioenhancement by Platinum Nanoparticles Under Conventional and Ultra‐High Dose‐Rate “FLASH” Radiotherapy

Small, EarlyView.
Overview of the experimental workflow and main findings of the study investigating Pt‐NPs‐mediated radioenhancement under conventional 134 dose‐rate (CONV) and ultrahigh dose‐rate (UHDR) 9 MeV electron irradiation. Pt‐NP distribution and uptake were characterized in 4T1 spheroids and syngeneic tumor models.
Cathyanne Schott, Foutina Feghali, Marine Gerbé de Thoré, Amina Joudat, Lydia Meziani, Aashini Rajpal, Winchygn Liu, Tudor Manoliu, Farah Savina, Sandrine Lacombe, Eric Deutsch, Julie Colnot, Charlotte Robert, Erika Porcel, Pauline Maury   +14 more
wiley   +1 more source

Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer. [PDF]

Transl Oncol
Lin TY, Chang FL, Hsieh SJ, Zheng JH, Lu YC, Cheng MH, Tsai KC, HuangFu WC, Hung CS, Lee YC.   +9 more
europepmc   +1 more source

HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer

Small, EarlyView.
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu, Nisha Wu, Zaihui Peng, Guozhi Zhang, Lin Ren, Qiuyun Li, Jie Xiao, Jing He, Yuxiuzi Xiao, Li Ma, Yi Zhang, Ying Gong, Xiaowei Qi   +12 more
wiley   +1 more source

Single‐Vesicle Functional Nanophenotyping Reveals Heterogeneous PD‐L1 Accessibility in Triple‐Negative Breast Cancer

Small Methods, EarlyView.
Graphical Abstract. High‐speed atomic force microscopy enables real‐time, label‐free visualization of antibody interactions with individual extracellular vesicles. By quantifying binding frequency and dwell time, this approach reveals functional PD‐L1 accessibility that cannot be inferred from protein abundance alone, uncovering nanoscale heterogeneity
Reon Imakawa, Keesiang Lim, Takeshi Yoshida, Tomoyoshi Yamano, Tsunaki Hongu, Uryo Onishi, Masaharu Hazawa, Toshio Ando, Noriko Gotoh, Rikinari Hanayama, Richard W. Wong   +10 more
wiley   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Geographic access to triple negative breast cancer clinical trials: are trials located near patients? [PDF]

Breast Cancer Res Treat
Amin LB, Kirkwood MK, Levit LA, Balogh EP, Waterhouse DM, Unger JM, Garrett-Mayer E, Chavez-MacGregor M.   +7 more
europepmc   +1 more source

Targeting hexokinase 2 to induce breast cancer cell senescence

British Journal of Pharmacology, EarlyView.
Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof, Katarina Cisarova, Sandra Burgstaller, Mia Schwerer, Markus Absenger‐Novak, Philipp J. Jost, Roland Malli, Wolfgang F. Graier, Robert Lukowski   +8 more
wiley   +1 more source

GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk. [PDF]

Cancers (Basel)
Du J, He X, Tang L, Liu H, Chen Q, Li S, Tu G, Li S.   +7 more
europepmc   +1 more source